News

Many at-risk Americans either do not know about PrEP or don't have access. Here's why raising awareness is key to ending the ...
LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...
"By improving awareness, access and trust in one of the most effective tools we have to prevent HIV," says the government's ...
The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice ...
WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.
A new study explores how healthcare providers can effectively implement Apretude for HIV pre-exposure prophylaxis (PrEP) among Black women.
Long-acting injectable PrEP may improve access, protection and adherence, especially for young people and pregnant women, according to Hasina Subedar, a senior technical advisor at South Africa’s ...
The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, lenacapavir, as a tool in their efforts to fight HIV infections – especially for ...
Yeztugo is the first and only twice-yearly option for HIV prevention available in the United States for those who may need or want PrEP.
Healthcare New HIV prevention shot touted as breakthrough: HealthLink HealthLink talked with a Seattle-based physician about why the newly approved drug could be a game-changer in preventing HIV.
Planned Parenthood of the Pacific Southwest has started offering an HIV prevention injection as part of its services.
Twice-yearly shot could improve PrEP adherence rates Despite advancements in HIV treatment and prevention, in 2023, more than 100 people were diagnosed with HIV every day in the United States.